SI2135878T1 - S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule človeškega levkocitnega antigena HLA Human Leukocyte Antigen razreda II - Google Patents
S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule človeškega levkocitnega antigena HLA Human Leukocyte Antigen razreda IIInfo
- Publication number
- SI2135878T1 SI2135878T1 SI200631206T SI200631206T SI2135878T1 SI 2135878 T1 SI2135878 T1 SI 2135878T1 SI 200631206 T SI200631206 T SI 200631206T SI 200631206 T SI200631206 T SI 200631206T SI 2135878 T1 SI2135878 T1 SI 2135878T1
- Authority
- SI
- Slovenia
- Prior art keywords
- molecules
- tumour
- present
- relates
- hla
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05019254A EP1760088B1 (en) | 2005-09-05 | 2005-09-05 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2135878T1 true SI2135878T1 (sl) | 2012-03-30 |
Family
ID=35170099
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200530167T SI1760088T1 (sl) | 2005-09-05 | 2005-09-05 | S tumorjem povezani peptidi, ki se veže z različnimi molekulami humanega levkocitnega antigena (HLA) razreda II |
| SI200531005T SI1806358T1 (sl) | 2005-09-05 | 2005-09-05 | S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II |
| SI200530994T SI1806359T1 (sl) | 2005-09-05 | 2005-09-05 | S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II |
| SI200631206T SI2135878T1 (sl) | 2005-09-05 | 2006-09-05 | S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule človeškega levkocitnega antigena HLA Human Leukocyte Antigen razreda II |
| SI200630566T SI1922335T1 (sl) | 2005-09-05 | 2006-09-05 | S tumorjem povezan peptid, ki se vedno veĹľe na molekule humanega levkocitnega antigena (HLA) razreda II |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200530167T SI1760088T1 (sl) | 2005-09-05 | 2005-09-05 | S tumorjem povezani peptidi, ki se veže z različnimi molekulami humanega levkocitnega antigena (HLA) razreda II |
| SI200531005T SI1806358T1 (sl) | 2005-09-05 | 2005-09-05 | S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II |
| SI200530994T SI1806359T1 (sl) | 2005-09-05 | 2005-09-05 | S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200630566T SI1922335T1 (sl) | 2005-09-05 | 2006-09-05 | S tumorjem povezan peptid, ki se vedno veĹľe na molekule humanega levkocitnega antigena (HLA) razreda II |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US10196432B2 (sl) |
| EP (6) | EP1806359B1 (sl) |
| JP (1) | JP5627180B2 (sl) |
| KR (3) | KR101386827B1 (sl) |
| CN (3) | CN103059104B (sl) |
| AT (5) | ATE461214T1 (sl) |
| AU (2) | AU2006289290B2 (sl) |
| BR (1) | BRPI0615462A2 (sl) |
| CA (2) | CA2621389C (sl) |
| CY (5) | CY1107973T1 (sl) |
| DE (4) | DE602005020047D1 (sl) |
| DK (5) | DK1760088T3 (sl) |
| EA (1) | EA013876B1 (sl) |
| ES (5) | ES2341802T3 (sl) |
| HK (2) | HK1183678A1 (sl) |
| HR (2) | HRP20100128T1 (sl) |
| NO (1) | NO340870B1 (sl) |
| NZ (2) | NZ566104A (sl) |
| PL (5) | PL1760088T3 (sl) |
| PT (5) | PT1806359E (sl) |
| SI (5) | SI1760088T1 (sl) |
| UA (1) | UA98295C2 (sl) |
| WO (1) | WO2007028574A2 (sl) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE461214T1 (de) * | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| SI2567707T1 (sl) | 2007-07-27 | 2017-01-31 | Immatics Biotechnologies Gmbh | Sestava s tumorjem povezanih peptidov in zadevnih cepiv proti raku |
| CA2694808C (en) | 2007-07-27 | 2015-10-13 | Immatics Biotechnologies Gmbh | Novel immunotherapy against neuronal and brain tumors |
| US8080634B2 (en) | 2007-07-27 | 2011-12-20 | Immatics Biotechnologies Gmbh | Immunogenic epitope for immunotherapy |
| JP5294271B2 (ja) | 2007-08-20 | 2013-09-18 | オンコセラピー・サイエンス株式会社 | Ｃｄｈ３ペプチド及びこれを含む薬剤 |
| EP3085707B1 (en) * | 2007-11-01 | 2019-02-27 | Mayo Foundation for Medical Education and Research | Hla-dr binding peptides and their uses |
| PL2105501T3 (pl) | 2008-03-27 | 2016-03-31 | Immatics Biotechnologies Gmbh | Innowacyjna immunoterapia przeciwko nowotworom neuronów i mózgu |
| DK2113253T3 (da) | 2008-04-30 | 2010-07-19 | Immatics Biotechnologies Gmbh | Ny sammensætning af tumorassocierede peptider, der bindes til humant leukocyt-antigen (HLA) klasse I eller II molekyler, til vaccinebrug |
| DK2119726T5 (en) | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| DK2172211T3 (en) | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| ES2552557T3 (es) | 2009-01-28 | 2015-11-30 | Industrial Technology Research Institute | Biomarcadores de la orina y el suero asociados con la nefropatía diabética |
| US9023802B2 (en) | 2009-12-14 | 2015-05-05 | Immatics Biotechnologies Gmbh | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| MX2013006758A (es) | 2010-12-14 | 2013-08-01 | Immatics Biotechnologies Gmbh | Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos. |
| CN106074601A (zh) * | 2011-03-23 | 2016-11-09 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| TWI777197B (zh) * | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（六） |
| PL3456339T3 (pl) | 2013-08-05 | 2022-03-21 | Immatics Biotechnologies Gmbh | Nowa immunoterapia przeciwko szeregu nowotworom, takim jak rak płuc, w tym nsclc |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| IL248203A0 (en) | 2014-05-09 | 2016-11-30 | Immatics Biotechnologies Gmbh | Innovative immunotherapy against blood tumors such as acute leukemia in the spinal cord |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| MA46913B1 (fr) | 2014-12-23 | 2021-09-30 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| MA42294B1 (fr) | 2015-07-01 | 2020-11-30 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| PT3319985T (pt) | 2015-07-06 | 2021-01-06 | Immatics Biotechnologies Gmbh | Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros |
| MY189596A (en) | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| UA125817C2 (uk) | 2015-08-28 | 2022-06-15 | Імматікс Біотекнолоджіс Гмбх | Пептид, придатний для лікування та/або діагностики раку |
| MY198087A (en) | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| PE20230343A1 (es) | 2015-12-11 | 2023-03-01 | Immatics Biotechnologies Gmbh | Peptidos que estimulan respuestas inmunitarias antitumorales |
| KR20180107102A (ko) | 2015-12-16 | 2018-10-01 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원 동정, 제조, 및 용도 |
| GB201522667D0 (en) * | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| CN116375797A (zh) | 2016-03-01 | 2023-07-04 | 伊玛提克斯生物技术有限公司 | 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物 |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| MA44524A (fr) * | 2016-03-31 | 2019-02-06 | Neon Therapeutics Inc | Néoantigènes et leurs procédés d'utilisation |
| BR112018070067A2 (pt) | 2016-04-06 | 2019-02-12 | Immatics Biotechnologies Gmbh | peptídeos e combinações de peptídeos para uso em imunoterapia contra lma e outros cânceres |
| MX2018012758A (es) | 2016-04-21 | 2019-01-31 | Immatics Biotechnologies Gmbh | Inmunoterapia contra el melanoma y otros tipos de cancer. |
| PE20181897A1 (es) | 2016-04-21 | 2018-12-11 | Immatics Biotechnologies Gmbh | Inmunoterapia contra el melanoma y otros tipos de cancer |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| RU2630647C1 (ru) * | 2016-05-27 | 2017-09-11 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА |
| EP4099015A1 (en) * | 2016-06-10 | 2022-12-07 | Gadeta B.V. | Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response |
| TWI796299B (zh) * | 2016-08-26 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| MA47367B1 (fr) | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| PE20191248A1 (es) | 2017-01-27 | 2019-09-18 | Immatics Biotechnologies Gmbh | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer |
| EA201991444A1 (ru) | 2017-01-27 | 2019-12-30 | Имматикс Байотекнолоджиз Гмбх | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака |
| WO2018145048A1 (en) * | 2017-02-06 | 2018-08-09 | Academia Sinica | Recombinant proteins and uses thereof |
| US11427614B2 (en) | 2017-04-10 | 2022-08-30 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
| MA49123A (fr) | 2017-04-10 | 2020-03-25 | Immatics Biotechnologies Gmbh | Peptides et combinaison de peptides à utiliser en immunothérapie contre les leucémies et d'autres cancers |
| TW201841937A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於白血病和其他癌症免疫治療的新穎肽和肽組合物 |
| CN111548405A (zh) | 2017-04-10 | 2020-08-18 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的肽及其肽组合物 |
| CA3068852A1 (en) | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers |
| WO2019007974A1 (en) | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS |
| JP7274462B2 (ja) | 2017-09-18 | 2023-05-16 | エスアンドピー・イングリーディエント・ディベロップメント・エルエルシー | 塩化カリウムを有する低ナトリウム塩代替物 |
| CN111465989A (zh) | 2017-10-10 | 2020-07-28 | 磨石肿瘤生物技术公司 | 使用热点进行的新抗原鉴别 |
| EP3714275A4 (en) | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| DE102018108996B4 (de) | 2018-02-09 | 2021-10-21 | Immatics US, Inc. | Verfahren zur Herstellung autologer T-Zellen |
| CN111684062A (zh) | 2018-02-09 | 2020-09-18 | 伊玛提克斯美国公司 | 制造t细胞的方法 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| JP7480064B2 (ja) * | 2018-02-27 | 2024-05-09 | グリットストーン バイオ インコーポレイテッド | パンアレルモデルによる新生抗原の特定方法 |
| EP3539562A1 (en) * | 2018-03-12 | 2019-09-18 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Immunotherapeutic peptides |
| TW202016131A (zh) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| KR102215578B1 (ko) * | 2019-03-28 | 2021-02-15 | 한국과학기술연구원 | 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| KR20220018006A (ko) | 2019-06-06 | 2022-02-14 | 이매틱스 바이오테크놀로지스 게엠베하 | 서열 유사 펩티드를 사용하는 계수기 선택에 의한 분류 |
| CN110305209B (zh) * | 2019-07-09 | 2022-09-13 | 福建医科大学附属第一医院 | 用于治疗恶性肿瘤的多肽及其作为疫苗的用途 |
| KR20220087431A (ko) * | 2019-07-30 | 2022-06-24 | 유니버시티 헬스 네트워크 | T 세포 수용체 및 이의 사용 방법 |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| US11891427B2 (en) | 2020-09-29 | 2024-02-06 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| TW202241925A (zh) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於不同類型癌症免疫治療的ｈｌａ展示肽 |
| WO2024077601A1 (en) * | 2022-10-14 | 2024-04-18 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Peptide vaccines against glioma and uses thereof |
| CN117720620A (zh) * | 2023-12-13 | 2024-03-19 | 无锡市儿童医院 | 小分子多肽和其药物组合物、其制药用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8212000B2 (en) * | 1970-02-11 | 2012-07-03 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US8211999B2 (en) * | 1970-02-11 | 2012-07-03 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US8258260B2 (en) * | 1970-02-11 | 2012-09-04 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| GR66050B (sl) * | 1977-09-20 | 1981-01-14 | Licinvest Ag | |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| YU44186B (en) | 1978-12-22 | 1990-04-30 | Biogen Nv | Process for obtaining recombinant dnk molecules |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4810781A (en) * | 1987-01-15 | 1989-03-07 | The George Washington University | Methods of preparing epitopes of tumor associated antigens |
| EP0636175A1 (en) * | 1992-04-03 | 1995-02-01 | La Jolla Cancer Research Foundation | Decorin fragments and methods of inhibiting cell regulatory factors |
| EP0671926B1 (en) * | 1992-08-11 | 2002-11-13 | President And Fellows Of Harvard College | Immunomodulatory peptides |
| US5889159A (en) * | 1993-10-29 | 1999-03-30 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies to tumor marker TC1 and methods for use of same |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| NZ290089A (en) | 1994-07-27 | 1999-05-28 | Queensland Inst Med Res | Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines |
| UY24367A1 (es) * | 1995-11-23 | 2000-10-31 | Boehringer Ingelheim Int | Vacunas contra tumores y procedimiento para su produccion |
| ATE244300T1 (de) | 1996-01-17 | 2003-07-15 | Imp College Innovations Ltd | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
| US6610821B1 (en) * | 1996-07-12 | 2003-08-26 | Mcgill University | Compounds and methods for modulating endothelial cell adhesion |
| US6046031A (en) * | 1997-01-21 | 2000-04-04 | Human Genome Sciences, Inc. | Metalloproteinases |
| US6316213B1 (en) * | 1997-03-19 | 2001-11-13 | The Board Of Trustees Of The University Of Arkansas | Methods for the early diagnosis of ovarian, breast and lung cancer |
| ATE302273T1 (de) * | 1997-10-15 | 2005-09-15 | Pharis Biotec Gmbh | Cadherin derived growth factor und seine verwendung |
| DE19757250A1 (de) * | 1997-12-22 | 1999-07-01 | Forssmann Wolf Georg Prof Dr | Insulin-like growth factor binding protein und seine Verwendung |
| US6746852B1 (en) * | 1998-05-08 | 2004-06-08 | Osi Pharmaceuticals, Inc. | AGS proteins and nucleic acid molecules and uses thereof |
| DE19936563A1 (de) | 1999-08-04 | 2001-02-08 | Boehringer Ingelheim Int | Tumorassoziiertes Antigen |
| DE19938583A1 (de) | 1999-08-18 | 2001-02-22 | Buehler Ag | Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial |
| AU2001236589A1 (en) * | 2000-02-04 | 2001-08-14 | Aeomica, Inc. | Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes |
| AU2001278076A1 (en) * | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-5 proteins and related reagents and methods of use thereof |
| WO2002050103A2 (en) | 2000-12-20 | 2002-06-27 | Glaxosmithkline Biologicals S.A. | Tumour-related antigens |
| AU2002303219A1 (en) * | 2001-03-30 | 2002-10-15 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| WO2003004989A2 (en) * | 2001-06-21 | 2003-01-16 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US7087727B2 (en) * | 2001-08-13 | 2006-08-08 | Dana-Farber Cancer Institute, Inc. | Periostin-based diagnostic assays |
| US6906036B2 (en) * | 2001-08-16 | 2005-06-14 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| WO2003030836A2 (en) * | 2001-10-12 | 2003-04-17 | Case Western Reserve University | Neuronal regeneration |
| US20050100554A1 (en) * | 2002-02-14 | 2005-05-12 | Amanda Jackson | Complexes and methods of using same |
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| WO2004014867A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Matrix metalloproteinase inhibitors and methods for identification of lead compounds |
| CA2500687A1 (en) * | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP1560597A4 (en) * | 2002-10-29 | 2007-06-27 | Pharmacia Corp | DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES |
| CN1839205B (zh) * | 2003-05-29 | 2012-05-16 | 千年药品公司 | 用于鉴定、评估、预防和治疗乳腺癌的组合物、试剂盒及方法 |
| US20080227125A1 (en) * | 2003-07-15 | 2008-09-18 | Guilaine Argoud-Puy | Secreted Polypeptide Species Reduced in Cardiovascular Disorders |
| EP1757940A1 (en) | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC |
| DE602005016112D1 (de) * | 2005-09-05 | 2009-10-01 | Immatics Biotechnologies Gmbh | Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe |
| ATE461214T1 (de) * | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| EP1795599A1 (en) * | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
-
2005
- 2005-09-05 AT AT07007914T patent/ATE461214T1/de active
- 2005-09-05 PL PL05019254T patent/PL1760088T3/pl unknown
- 2005-09-05 DE DE602005020047T patent/DE602005020047D1/de active Active
- 2005-09-05 DE DE602005005196T patent/DE602005005196T2/de active Active
- 2005-09-05 DE DE602005020046T patent/DE602005020046D1/de active Active
- 2005-09-05 PT PT07007915T patent/PT1806359E/pt unknown
- 2005-09-05 ES ES07007914T patent/ES2341802T3/es active Active
- 2005-09-05 PL PL07007914T patent/PL1806358T3/pl unknown
- 2005-09-05 DK DK05019254T patent/DK1760088T3/da active
- 2005-09-05 SI SI200530167T patent/SI1760088T1/sl unknown
- 2005-09-05 AT AT05019254T patent/ATE388164T1/de active
- 2005-09-05 EP EP07007915A patent/EP1806359B1/en not_active Not-in-force
- 2005-09-05 PL PL07007915T patent/PL1806359T3/pl unknown
- 2005-09-05 EP EP07007914A patent/EP1806358B1/en not_active Not-in-force
- 2005-09-05 ES ES05019254T patent/ES2302546T3/es active Active
- 2005-09-05 PT PT05019254T patent/PT1760088E/pt unknown
- 2005-09-05 EP EP05019254A patent/EP1760088B1/en not_active Not-in-force
- 2005-09-05 ES ES07007915T patent/ES2341295T3/es active Active
- 2005-09-05 AT AT07007915T patent/ATE461215T1/de active
- 2005-09-05 SI SI200531005T patent/SI1806358T1/sl unknown
- 2005-09-05 SI SI200530994T patent/SI1806359T1/sl unknown
- 2005-09-05 DK DK07007914.0T patent/DK1806358T3/da active
- 2005-09-05 PT PT07007914T patent/PT1806358E/pt unknown
- 2005-09-05 DK DK07007915.7T patent/DK1806359T3/da active
-
2006
- 2006-09-05 KR KR1020137002915A patent/KR101386827B1/ko not_active IP Right Cessation
- 2006-09-05 DK DK06791838.3T patent/DK1922335T3/da active
- 2006-09-05 SI SI200631206T patent/SI2135878T1/sl unknown
- 2006-09-05 AT AT06791838T patent/ATE451388T1/de active
- 2006-09-05 US US11/912,670 patent/US10196432B2/en active Active
- 2006-09-05 CN CN201210560635.8A patent/CN103059104B/zh not_active Expired - Fee Related
- 2006-09-05 AT AT09011319T patent/ATE532795T1/de active
- 2006-09-05 BR BRPI0615462-0A patent/BRPI0615462A2/pt not_active Application Discontinuation
- 2006-09-05 PL PL09011319T patent/PL2135878T3/pl unknown
- 2006-09-05 NZ NZ566104A patent/NZ566104A/en not_active IP Right Cessation
- 2006-09-05 CN CN2006800383657A patent/CN101287754B/zh not_active Expired - Fee Related
- 2006-09-05 CA CA2621389A patent/CA2621389C/en not_active Expired - Fee Related
- 2006-09-05 ES ES06791838T patent/ES2337399T3/es active Active
- 2006-09-05 KR KR1020137002917A patent/KR101386790B1/ko not_active IP Right Cessation
- 2006-09-05 SI SI200630566T patent/SI1922335T1/sl unknown
- 2006-09-05 PT PT06791838T patent/PT1922335E/pt unknown
- 2006-09-05 ES ES09011319T patent/ES2373907T3/es active Active
- 2006-09-05 DE DE602006011030T patent/DE602006011030D1/de active Active
- 2006-09-05 PL PL06791838T patent/PL1922335T3/pl unknown
- 2006-09-05 DK DK09011319.2T patent/DK2135878T3/da active
- 2006-09-05 WO PCT/EP2006/008642 patent/WO2007028574A2/en active Application Filing
- 2006-09-05 EP EP09011317A patent/EP2138509A1/en not_active Withdrawn
- 2006-09-05 CN CN201510571930.7A patent/CN105440119A/zh active Pending
- 2006-09-05 NZ NZ588813A patent/NZ588813A/en not_active IP Right Cessation
- 2006-09-05 KR KR1020087008073A patent/KR101386355B1/ko not_active IP Right Cessation
- 2006-09-05 JP JP2008528438A patent/JP5627180B2/ja not_active Expired - Fee Related
- 2006-09-05 EA EA200800677A patent/EA013876B1/ru not_active IP Right Cessation
- 2006-09-05 CA CA2929252A patent/CA2929252A1/en not_active Abandoned
- 2006-09-05 EP EP09011319A patent/EP2135878B1/en active Active
- 2006-09-05 PT PT09011319T patent/PT2135878E/pt unknown
- 2006-09-05 AU AU2006289290A patent/AU2006289290B2/en not_active Ceased
- 2006-09-05 EP EP06791838A patent/EP1922335B1/en active Active
- 2006-09-05 UA UAA200803825A patent/UA98295C2/ru unknown
-
2007
- 2007-11-19 US US11/942,620 patent/US7833970B2/en active Active
- 2007-11-19 US US11/942,394 patent/US20080206216A1/en not_active Abandoned
- 2007-11-19 US US11/942,598 patent/US7833969B2/en active Active
- 2007-11-19 US US11/942,573 patent/US7807642B2/en active Active
-
2008
- 2008-04-04 NO NO20081683A patent/NO340870B1/no not_active IP Right Cessation
- 2008-05-28 CY CY20081100554T patent/CY1107973T1/el unknown
-
2010
- 2010-02-19 CY CY20101100169T patent/CY1109849T1/el unknown
- 2010-03-09 HR HR20100128T patent/HRP20100128T1/hr unknown
- 2010-05-27 CY CY20101100469T patent/CY1110051T1/el unknown
- 2010-06-11 CY CY20101100520T patent/CY1110187T1/el unknown
- 2010-10-26 AU AU2010236029A patent/AU2010236029B2/en not_active Ceased
-
2011
- 2011-12-09 CY CY20111101223T patent/CY1112186T1/el unknown
- 2011-12-30 HR HR20110981T patent/HRP20110981T1/hr unknown
-
2013
- 2013-10-02 HK HK13111197.3A patent/HK1183678A1/xx not_active IP Right Cessation
-
2015
- 2015-11-05 US US14/933,077 patent/US10618945B2/en active Active
-
2016
- 2016-07-26 HK HK16108913.9A patent/HK1220709A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1220709A1 (zh) | 混雜地結合於人類白細胞抗原 類分子的腫瘤相關肽 | |
| HRP20110240T1 (en) | Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine | |
| SI1794190T1 (sl) | Imunogeni T-pomagalni epitopi iz humanih tumornih antigenov in imunoterapevtski postopki, ki uporabljajo navedene epitope |